1253197-38-4
Chemical Structure
WMS-1410
- CAS No.: 1253197-38-4
- Formula:C20H25NO2
- Molecular Weight:311.42
InChIKey: KKLZGWQBNXJWGZ-UHFFFAOYSA-N
SMILES: OC1=CC=C2C(CCN(CC2O)CCCCC3=CC=CC=C3)=C1
Biological Activity: WMS-1410 is a selective GluN2B-containing NMDA receptor inhibitor with an IC50 of 18.4 nM. WMS-1410 regulates intracellular calcium levels and protects cells from Apoptosis. WMS-1410 inhibits glutamate-induced excitotoxicity. WMS-1410 reverses NMDA/glycine-induced reduction in glucose-stimulated insulin secretion without altering physiological insulin secretion or baseline redox status, but fails to counteract insulin content loss induced by glucolipotoxicity. WMS-1410 exhibits analgesic activity against advanced neuropathic pain. WMS-1410 can be used in studies related to stroke, brain injury, Alzheimer's disease, Parkinson's disease, type 2 diabetes, and neuropathic pain[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
WMS-1410 | WMS-1410 is a selective GluN2B-containing NMDA receptor inhibitor with an IC50 of 18.4 nM. WMS-1410 regulates intracellular calcium levels and protects cells from Apoptosis. WMS-1410 inhibits glutamate-induced excitotoxicity. WMS-1410 reverses NMDA/glycine-induced reduction in glucose-stimulated insulin secretion without altering physiological insulin secretion or baseline redox status, but fails to counteract insulin content loss induced by glucolipotoxicity. WMS-1410 exhibits analgesic activity against advanced neuropathic pain. WMS-1410 can be used in studies related to stroke, brain injury, Alzheimer's disease, Parkinson's disease, type 2 diabetes, and neuropathic pain. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Falck E, et al. In vitro and in vivo biotransformation of WMS-1410, a potent GluN2B selective NMDA receptor antagonist. J Pharm Biomed Anal. 2014;94:36-44. [Content Brief]
- [2]. Gresch A, et al. Selective Inhibition of N-Methyl-d-aspartate Receptors with GluN2B Subunit Protects β Cells against Stress-Induced Apoptotic Cell Death. J Pharmacol Exp Ther. 2021;379(3):235-244. [Content Brief]
- [3]. Tewes B, et al. Conformationally constrained NR2B selective NMDA receptor antagonists derived from ifenprodil: Synthesis and biological evaluation of tetrahydro-3-benzazepine-1,7-diols. Bioorg Med Chem. 2010;18(22):8005-8015. [Content Brief]
Keywords
